Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Biohaven Ltd. (BHVN) Price & Analysis

BHVN Stock Chart & Stats

$15.42-$1.07(-6.49%)
At close: 4:00 PM EDT
$12$14$163 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$15.12 - $16.33
52-Week Range
$7.48 - $18.24
Previous Close
$16.49
Volume
1.72M
Average Volume (3M)
3.19M
Market Cap
$2.33B
Enterprise Value
$2.15B
Total Cash (Recent Filing)
$161.13M
Total Debt (Recent Filing)
$300.44M
Price to Earnings (P/E)
―
Beta
1.57
Next Earnings
Mar 08, 2027
EPS Estimate
0.07
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Non-dilutive Kv7 Licensing

The SK partnership converts the Kv7 platform into substantial non-dilutive funding while preserving royalty participation. By transferring commercialization responsibilities and receiving milestone potential, Biohaven can support broader pipeline development with less reliance on equity financing.

Asian IgG Degrader Partnership

The Ono agreement validates Biohaven’s MoDE IgG degrader platform through a regional pharmaceutical partner and supplies near-term capital. Retained rights outside Asia and meaningful royalties preserve participation in future growth while Ono funds regional development and commercialization.

Vyglxia Regulatory Progress

Acceptance of the resubmitted NDA moves Vyglxia into an active FDA review process and provides a defined regulatory milestone for the rare-disease portfolio. The filing’s supportive analyses and planned advisory committee add important validation, although approval remains uncertain.

Bears Say

Pre-revenue Operating Model

Biohaven has not yet demonstrated commercial revenue or positive unit economics, leaving its financial profile dependent on pipeline progress and partnership proceeds. Persistent losses reduce internal funding capacity and make future profitability reliant on successful development and commercialization.

Sustained Cash Burn

Large recurring operating cash outflows create continuing funding needs while the company remains pre-revenue. Because free cash flow is also negative and the latest trend is not clearly stabilizing, Biohaven has limited ability to finance development internally over the next several quarters.

Deteriorated Balance Sheet

Higher debt combined with negative equity materially reduces financial flexibility and increases leverage risk. The decline in total assets alongside persistent losses suggests that capital pressure remains significant, potentially constraining investment choices and increasing dependence on external funding.

Biohaven Ltd. News

BHVN FAQ

What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.24 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $2.33B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 08, 2027 which is in 127 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Oct 29, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.783 by -$0.077.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 151,058,780 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.783. Following the earnings report the stock price went down -6.489%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology